Endologix Presents Promising DETOUR2 Study Final Results
Endologix LLC, a pioneering medical device company, has made significant strides with the launch of its DETOUR2 Study. This extensive study sheds light on the outcomes of the DETOUR System, tailored specifically for complex peripheral arterial disease (PAD). By utilizing stents through the femoral vein, this innovative approach aims to enhance blood flow effectively to the legs while sidestepping the challenges associated with traditional surgical methods.
Understanding the DETOUR System
The technology behind the DETOUR System includes the ENDOCROSS device and TORUS stent grafts. These components are integral to the clinical approach that permits the treatment of obstructive arterial conditions. The recent study results have showcased that this technology not only meets but often exceeds expectations when compared to conventional surgical interventions, particularly in delivering safe and effective results.
The Importance of 36-Month Results
During a recent clinical presentation, one of the principal investigators, Dr. Sean Lyden, highlighted that the DETOUR System's performance over a 36-month period is unprecedented. Dr. Lyden emphasized that patients benefit from this method without needing general anesthesia, which typically introduces additional risks and prolonged recovery times. This finding is particularly significant for patients who may face complications from traditional bypass surgeries.
Clinical Findings from the Study
The DETOUR2 Study tracked a substantial cohort of patients, with 202 enrolled across multiple sites. Of these, 200 patients received the DETOUR treatment, demonstrating remarkable outcomes. Key performance indicators included:
- 66.8% freedom from clinically driven target limb revascularization (CD-TLR) over three years.
- 58.2% primary patency at the same time frame.
- Clinical success was noted in a significant 96.7% of patients.
- 95.9% freedom from symptomatic deep venous thrombosis (DVT).
- 98.5% freedom from major lower limb amputation.
- An impressive average hospital stay of just 1.1 days.
Why DETOUR2 is a Game Changer
The findings from this study are not just numbers; they represent a shift in the treatment paradigm for long segment superficial femoral artery (SFA) disease. Dr. Matt Thompson, President and CEO of Endologix, expressed optimism regarding the implications of these results. He noted that the DETOUR System among healthcare providers could lead to more effective, less invasive treatment options for patients facing challenging vascular conditions.
Innovations to Improve Patient Outcomes
As Endologix continues its mission, the company remains committed to enhancing data collection, rigorous training, and additional studies to validate the DETOUR System's efficacy in diverse real-world scenarios. This multifaceted approach underscores their dedication to delivering optimal patient outcomes and further enhancing the overall treatment landscape for vascular diseases.
About Endologix LLC
Endologix LLC is dedicated to transforming patient care in vascular treatment. The company's portfolio consists of advanced medical technologies aimed at addressing various vascular diseases that have presented unmet clinical needs. With their commitment to innovation, Endologix strives to provide effective solutions for conditions like abdominal aortic aneurysms and peripheral vascular disease.
Frequently Asked Questions
What is the DETOUR System?
The DETOUR System is a method developed to treat complex peripheral arterial disease by using stents routed through the femoral vein, designed to restore blood flow effectively.
How many patients were involved in the DETOUR2 Study?
There were 202 patients enrolled in the DETOUR2 Study, with 200 of them receiving the treatment with the DETOUR System.
What were some key outcomes demonstrated in the DETOUR2 Study?
Key outcomes included 66.8% freedom from clinically driven target limb revascularization and 58.2% primary patency over three years.
Why is the DETOUR System considered innovative?
The DETOUR System is considered innovative as it offers a less invasive alternative to traditional surgical methods, thus minimizing complications related to anesthesia and recovery time.
What is Endologix’s commitment to patient care?
Endologix is committed to improving patient outcomes through continued innovation, rigorous training, and ongoing research to validate their treatment methods.
